INDV · Indivior Pharmaceuticals Inc
The AI's read
Indivior announced an all-stock merger with Supernus to form a larger CNS-focused pharma with a combined commercial portfolio and ~$2.2B pro forma revenue. Management flags $125M in annual cost synergies, adjusted EBITDA of $888M, and net leverage near 1x, so scale and cash flow improve. The stock is only up ~2% today, so the market has acknowledged the news but hasn’t fully repriced the combined economics. That modest move suggests there’s still upside optionality if integration goes smoothly and synergies are realized. We lean bullish. Bigger product mix, clearer cash generation, and $125M of synergies create asymmetric upside versus today's small price move, and the deal structure is all-stock which lowers near-term cash strain. Conviction 90% because the information is fresh, quantifiable, and the market reaction is limited rather than stretched.